63927-22-0

Basic information

• Product Name: 8-Bromoisoquinoline
• Synonyms: 8-BROMOISOQUINOLINE;8-Bromoisoquinoline 95%;Isoquinoline, 8-bromo-;8-Bromoisoquinoline ,97%
• CAS NO: 63927-22-0
• Molecular Formula: C₉H₆BrN
• Molecular Weight: 208.05
• EINECS: -0
• Product Categories: blocks;Bromides;Heterocycles;Quinolines;Quinoline series;Heterocyclic Series;Halides;Quinolines, Isoquinolines & Quinoxalines;Quinoline&Isoquinoline;Isoquinoline Derivertives;Building Blocks;Isoquinoline;Quinolines, Isoquinolines & Quinoxalines;C8 to C10;Chemical Synthesis;Heterocyclic Building Blocks;New Products for Chemical Synthesis
• Mol File: 63927-22-0.mol

Chemical Properties

• Melting Point: 80,5 C
• Boiling Point: 312.3 °C at 760 mmHg
• Flash Point: 142.7 °C
• Appearance: /
• Density: 1.564 g/cm³
• Vapor Pressure: 0.0101mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.63±0.23(Predicted)
• CAS DataBase Reference: 8-Bromoisoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Bromoisoquinoline(63927-22-0)
• EPA Substance Registry System: 8-Bromoisoquinoline(63927-22-0)

Safety Data

• Hazard Codes: Xi,Xn,T
• Statements: 36/37/38-20/21/22-25
• Safety Statements: 26-36-45
• RIDADR: 2811
• HazardClass: 6.1
• PackingGroup: Ⅲ
• Hazardous Substances Data: 63927-22-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
8-Bromoisoquinoline is used as a chemical intermediate for the preparation of 4-?((2-?Hydroxy-?3-?methoxybenzyl)?amino)?benzenesulfonamide derivatives. These derivatives exhibit potent and selective inhibitory activity against 12-?Lipoxygenase, an enzyme involved in various inflammatory processes. By targeting this enzyme, these derivatives have potential therapeutic applications in treating inflammatory diseases.
Additionally, 8-Bromoisoquinoline is utilized in the synthesis of selective excitatory amino acid transporter subtype 1 (EAAT1) Inhibitor UCPH-?102. EAAT1 is a membrane transporter responsible for the reuptake of excitatory neurotransmitters, such as glutamate, in the central nervous system. Inhibition of EAAT1 can lead to increased extracellular glutamate levels, which may have implications in the treatment of neurological disorders associated with glutamate dysregulation.

InChI:InChI=1/C12H13N/c1-9(2)12-11-6-4-3-5-10(11)7-8-13-12/h3-9H,1-2H3

Upstream product

• 7664-93-9 sulfuric acid 
• 63927-19-5 (2-bromo-benzylidenamino)-acetaldehyde diethylacetal 
• 119-65-3 isoquinoline 
• 23687-27-6 8-aminoisoquinoline 
• 6630-33-7 ortho-bromobenzaldehyde 
• 14000-31-8 pyrophosphoric acid 
• 645-36-3 2,2-diethoxy-ethanamine 
• 3132-99-8 m-bromobenzoic aldehyde 
• 22483-09-6 2,2-dimethoxyethylamine 
• 1239460-78-6 2-bromo-N-(2,2-dimethyloxyethylidene)aniline 
• 63927-23-1 5-bromo-8-nitroisoquinoline 
• 34784-04-8 5-bromoisoquinoline 
• 405161-29-7 (2-bromobenzylidene)(2,2-dimethoxyethyl)amine 

Downstream Products

• 362606-11-9 isoquinoline-8-carbonitrile 
• 475994-58-2 8-bromo-2-oxidoisoquinolin-2-ium 
• 105685-27-6 8-(piperazin-1-yl)isoquinoline 
• 863290-47-5 2-benzoyl-8-bromo-1-cyano-1,2-dihydroisoquinoline 
• 863290-55-5 8-bromo-1-(3,4-dimethoxy-benzyl)-isoquinoline 
• 444620-33-1 4-isoquinolin-8-yl-piperazine-1-carboxylic acid tert-butyl ester 
• 444620-35-3 1-(8-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-ethanone 
• 444620-44-4 2-methanesulfonyl-8-piperazin-1-yl-1,2,3,4-tetrahydro-isoquinoline 
• 444620-48-8 8-piperazin-1-yl-2-(propane-2-sulfonyl)-1,2,3,4-tetrahydro-isoquinoline 
• 444620-34-2 4-(1,2,3,4-tetrahydro-isoquinolin-8-yl)-piperazine-1-carboxylic acid tert-butyl ester 
• 444620-47-7 2-benzenesulfonyl-8-piperazin-1-yl-1,2,3,4-tetrahydro-isoquinoline 

Relevant articles and documents

ISOXAZOLINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS

Disclosed are compounds of Formula 1, wherein R1, R2, R3 and J are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the disclosure.

HETEROCYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS

The present invention provides a compound represented by the formula (1): wherein each symbol is as defined in the specification or a salt thereof has an EP4 receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of EP4 receptor associated diseases (e.g., rheumatoid arthritis, aortic aneurysm, endometriosis, ankylosing spondylitis, inflammatory breast cancer etc.) and the like.

INHIBITORS OF JUN N-TERMINAL KINASE

The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula (I): or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.

3,5-Disubstituted quinolines as novel c-Jun N-terminal kinase inhibitors

The structure-based design and synthesis of a novel series of c-Jun N-terminal kinase (JNK) inhibitors with selectivity against p38 is reported. The unique structure of 3,5-disubstituted quinolines (2) was developed from the previously reported 4-(2,7-phenanthrolin-9-yl)phenol (1). The X-ray crystal structure of 16a in JNK3 reveals an unexpected binding mode for this new scaffold with protein.

Synthesis and radioligand binding studies of C-5- and C-8-substituted 1-(3,4-dimethoxybenzyl)-2,2-dimethyl-1,2,3,4-tetrahydroisoquinoliniums as SK channel blockers related to N-methyl-laudanosine and N-methyl-noscapine

The synthesis and the 125I-apamin binding studies of original C-5- and C-8-substituted 1-(3,4-dimethoxy-benzyl)-2,2-dimethyl-1,2,3,4- tetrahydroisoquinoliniums and 1-(3,4-dimethoxy-benzyl)-6,6-dimethyl-4,5,6,7- tetrahydrothieno[2,3-c]pyridiniums were performed in order to find a reversible and selective SK channel blocker structurally related to N-methyl-laudanosine and N-methyl-noscapine. A bulky alkyl substituent in the C-8 position of the tetrahydroisoquinoline produces a clear increase in the affinity for the apamin sensitive binding sites. The presence of an electron-withdrawing group in the C-5 and C-8 positions is not a suitable substitution for the affinity of drugs structurally related to N-methyl-laudanosine. Thiophenic analogues and 8-methoxy derivatives possess a poor affinity for the apamin sensitive binding sites. Electrophysiological studies performed with the most effective compound showed a blockade of the apamin sensitive afterhyperpolarization in rat dopaminergic neurons.

THROMBIN INHIBITORS

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions and are selected from the group consisting of: or a pharmaceutically acceptable salt thereof, wherein T is selected from the group consisting of D, E, F, G, H, I, and J are independently N or CY 1, provided that the number of such variables D, E, F, G, H, I, and J representing N is 0, 1, or 2; K, L, M and Q are independently NH or CY1Y2, provided that the number of such variables D, E, F, K, L, M, and Q representing N is 0, 1, or 2; Y1 and Y2 are independently selected from the group consisting of hydrogen, C1-4 alkyl, halogen, anino, or hydroxy; A is

Synthesis of novel substituted isoquinolones

A series of novel substituted isoquinolones have been synthesised. This has been achieved by two routes, either Curtius rearrangment of cinnamic acids or via an isoquinoline N-oxide.

Bromination of isoquinoline, quinoline, quinazoline and quinoxaline in strong acid

Bromination of benzazines and benzodiazines most often gives a mixture of products. In this paper, we show that isoquinoline (1) may be regioselectively monobrominated in concentrated H2SO4 using NBS or in CF3SO3H using N,N′-dibromoisocyanuric acid (DBI) to give 5-bromoisoquinoline (2). The bromination was found to be highly sensitive to the choice of brominating agent, acid, temperature and concentration. Quinoline, quinazoline and quinoxaline may be brominated likewise, although with the strong regioselectivity reserved to isoquinoline.